117 related articles for article (PubMed ID: 33477103)
21. Severe Hypoglycemia Before Landing in a Patient with Type 1 Diabetes Using Sensor-Augmented Pump Therapy.
Viñals C; Pané A; Quirós C; Giménez M; Conget I
Diabetes Technol Ther; 2017 Aug; 19(8):491-492. PubMed ID: 28594566
[No Abstract] [Full Text] [Related]
22. [Sensor-Augmented Pump Therapy: description of pediatric patients with Type 1 Diabetes Mellitus (T1D) and initial metabolic outcomes].
Wong Lam C; Hurtado Navarro J; Fuentes Díaz R; Toro Toro E; Reyes Espejo B
Andes Pediatr; 2022 Dec; 93(6):860-867. PubMed ID: 37906803
[TBL] [Abstract][Full Text] [Related]
23. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
[TBL] [Abstract][Full Text] [Related]
24. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
[TBL] [Abstract][Full Text] [Related]
25. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects.
Davis SN; Horton ES; Battelino T; Rubin RR; Schulman KA; Tamborlane WV
Diabetes Technol Ther; 2010 Apr; 12(4):249-55. PubMed ID: 20210562
[TBL] [Abstract][Full Text] [Related]
26. The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.
Katayama A; Tone A; Watanabe M; Teshigawara S; Miyamoto S; Eguchi J; Nakatsuka A; Shikata K; Wada J
Diabetol Int; 2020 Apr; 11(2):97-104. PubMed ID: 32206479
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of SmartGuard Technology in the Prevention of Nocturnal Hypoglycemia After Prolonged Physical Activity.
Petruzelkova L; Pickova K; Sumnik Z; Soupal J; Obermannova B
Diabetes Technol Ther; 2017 May; 19(5):299-304. PubMed ID: 28520532
[TBL] [Abstract][Full Text] [Related]
28. Effects of performing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor-augmented insulin pump therapy.
Gomez AM; Gomez C; Aschner P; Veloza A; Muñoz O; Rubio C; Vallejo S
J Diabetes Sci Technol; 2015 May; 9(3):619-24. PubMed ID: 25555390
[TBL] [Abstract][Full Text] [Related]
29. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
31. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.
Weiss R; Garg SK; Bergenstal RM; Klonoff DC; Bode BW; Bailey TS; Thrasher J; Schwartz F; Welsh JB; Kaufman FR;
J Diabetes Sci Technol; 2015 May; 9(5):1016-20. PubMed ID: 25986629
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a Predictive Low-Glucose Management System In-Clinic.
Buckingham BA; Bailey TS; Christiansen M; Garg S; Weinzimer S; Bode B; Anderson SM; Brazg R; Ly TT; Kaufman FR
Diabetes Technol Ther; 2017 May; 19(5):288-292. PubMed ID: 28221823
[TBL] [Abstract][Full Text] [Related]
34. Effect of real-life insulin pump with predictive low-glucose management use for 3 months: Analysis of the patients treated in a Japanese center.
Tsunemi A; Sato J; Kurita M; Wakabayashi Y; Waseda N; Koshibu M; Shinohara M; Ozaki A; Nakamura H; Hirano N; Ikeda F; Satoh H; Watada H
J Diabetes Investig; 2020 Nov; 11(6):1564-1569. PubMed ID: 32374513
[TBL] [Abstract][Full Text] [Related]
35. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
[TBL] [Abstract][Full Text] [Related]
36. Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring.
Henriksen MM; Andersen HU; Thorsteinsson B; Pedersen-Bjergaard U
J Clin Endocrinol Metab; 2018 Jun; 103(6):2329-2335. PubMed ID: 29618010
[TBL] [Abstract][Full Text] [Related]
37. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
Gómez AM; Marín Sánchez A; Muñoz OM; Colón Peña CA
Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
[TBL] [Abstract][Full Text] [Related]
38. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.
Garg S; Brazg RL; Bailey TS; Buckingham BA; Slover RH; Klonoff DC; Shin J; Welsh JB; Kaufman FR
Diabetes Technol Ther; 2012 Mar; 14(3):205-9. PubMed ID: 22316089
[TBL] [Abstract][Full Text] [Related]
39. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
